Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers

Journal of Controlled Release

Volumn 52, Issue 1-2, 1998, Pages 119-129

  Muraoka, Motoki ^a   Hu, Zhaopeng ^a   Shimokawa, Tatsuharu ^a   Sekino, Syu Ichi ^a   Kurogoshi, Ri E ^a   Kuboi, Yoshiko ^a   Yoshikawa, Yukako ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Colon delivery; Colon luminal pressure; Ethylcellulose; Intestinal luminal pressure controlled colon delivery capsule; Non compartmental pharmacokinetic analysis

Indexed keywords

CAFFEINE; ETHYL CELLULOSE; GELATIN;

ADULT; ARTICLE; DRUG CONTROL; DRUG DELIVERY SYSTEM; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE PRESSURE; MALE; PERISTALSIS; PRIORITY JOURNAL; SALIVA ANALYSIS; STOMACH EMPTYING; VOLUNTEER;

ADULT; CAFFEINE; CAPSULES; CELLULOSE; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FOOD; HUMANS; MALE; PRESSURE; SALIVA;

EID: 0032473475     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00201-0     Document Type: Article

References (44)

1. Hawthorne A.B., Hawkey C.J. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy. Drugs. 38:1989;267-288.
2. Stephen H.B. Drug Therapy. 334:1996;841-848.
3. Yu D.K., Morrill B., Eichmeier L.S., Lanman R.C., Lanman M.B., Giesing D.H., Weir S.J. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur. J. Clin. Pharmacol. 48:1995;273-277.
4. Davis S.S. Delivery systems for biopharmaceuticals. J. Pharm. Pharmacol. 44:1992;186-190.
5. Kraeling M.E.K., Ritschel W.A. Development of colonic release capsule iosage form and the absorption of insulin. Meth. Find. Exp. Clin. Pharmacol. 14:1992;199-209.
6. O'Hagan D.T., Palin K.J., Davis S.S. Intestinal absorption of proteins and macromolecules and the immunological response. CRC Crit. Rev. Ther. Drug Carrier Sys. 4:1987;197-220.
7. Lee V.H.L. Enzymatic barriers to peptide and protein absorption. CRC Crit. Rev. Ther. Drug Camer Sys. 5:1988;69-97.
8. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Sys. 11:1994;61-95.
9. Mrsny R.J. The colon as a site for drug delivery. J. Control. Rel. 22:1992;15-34.
10. D.R. Friend, Oral colon-specific drug delivery; CRC Press, Inc., Florida, (1992).
11. Saffran M., Kumar G.S., Savariar C., Burnham J.C., William F., Neckevs D.C. A new approach to the oral administration of insulin and other peptide drugs. Science. 233:1980;1081-1084.
12. Brøndsted H., Kopeček J. Hydrogels for site-specific drug delivery to the colon: In vitro and in vivo degradation. Pharm. Res. 9:1992;1540-1545.
13. Kraeling M.E.K., Ritschel W.A. Development of colonic release capsule iosage form and the absorption of insulin. Meth. Find. Exp. Clin. Pharmacol. 14:1992;199-209.
14. Gazzaniga A., Iamartino P., Maffone G., Sangalli M.E. Oral delayed-release system for colonic specific delivery. Int. J. Pharm. 108:1994;77-83.
15. Ashford M., Fell J., Attwood D., Sharma H., Woodhead P. Studies on pectin formulations for colonic drug delivery. J. Control. Rel. 30:1994;225-232.
16. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carrier Sys. 12:1995;101-149.
17. Hovgaard L., Brøndsted H. Dextran hydrogels for colon-specific drug delivery. Control. Rel. 36:1995;159-166.
18. Gazzaniga A., Busetti C., Moro L., Sangalli M.E., Giordano F. Time-dependent oral delivery systems for colon targeting. S.T.P. Pharm. Sci. 1:1995;83-88.
19. Wakerly Z., Fell J.T., Attwood D., Parkins D.A. In vitro evaluation of pectin-based colonic drug delivery systems. Int. J. Pharm. 129:1996;73-77.
20. Niwa K., Takaya T., Morimoto T., Takada K. Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J. Drug Target. 3:1995;83-89.
21. Takaya T., Ikeda C., Imagawa N., Niwa K., Takada K. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CFS) in beagle dogs. J. Pharm. Pharmacol. 47:1995;474-478.
22. Digenis G.A., Sandefer E. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms Crit. Rev. Ther. Drug Carrier Sys. 7:1991;309-345.
23. Ritschel W.A. Targeting in the gastrointestinal tract: New approaches. Meth. Find. Exp. Clin. Pharmacol. 13:1991;313-336.
24. Moës A.J. Gastroretentive dosage forms, Crit Rev. Ther. Drug Carrier Sys. 10:1993;143-195.
25. Takaya T., Sawada K., Suzuki H., Funaoka A., Matsuda K., Takada K. Application of colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. J. Drug Target. 4:1997;271-276.
26. Matsuda K., Takaya T., Shimoji F., Muraoka M., Yoshikawa Y., Takada K. Effect of food intake on the delivery of fluorescein as a model drug in colon delivery capsule after oral administration to beagle dogs. J. Drug Target. 4:1996;59-67.
27. Haeckel R., Hänecke P. Application of saliva for drug monitoring: An in vivo model for transmembrane transport. Eur. J. Clin. Biochem. 34:1996;171-191.
28. Melander A. Influence of food on the bioavailability of drugs. Clin. Pharmacokinet. 3:1978;337-351.
29. Tanaka E. Simultaneous determination of caffeine and its primary demethylated metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. 575:1992;311-314.
30. M. Gibaldi, D. Perrier, Pharmacokinetics; Marcel Dekker, Inc., New York, (1982).
31. Yoshikawa Y., Ohta S., Takada K. A computer program for the analysis of chromatograms used in pharmacokinetic studies. Int. J. Bio-Med. Comput. 47:1995;474-478.
32. Zuidema J., van Ginneken C.A.M. Clearance concept in salivary drug excretion. Pharm. Acta Helv. 58:1983;88-93.
33. Zylber-Katz E., Granit L., Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin. Pharmacol. Ther. 36:1984;133-137.
34. Lee T.C., Charles B.G., Steer P.A., Flenady W.J. Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. Ther. Drug Monit. 18:1996;288-293.
35. Cook C.E., Tallent C.R., Amerson E.W., Myers M.W., Kepler J.A., Taylor G.F., Christensen H.D. Caffeine in plasma and saliva by a radioimmunoassay procedure. J. Pharmacol. Exp. Ther. 199:1976;679-686.
36. Wilding I.R., Sparrow R.A., Davis S.S., Horton R.J. The role of gastric emptying in the absorption and metabolism of nifedipine given in a modified release pellet formulation. Int. J. Pharm. 84:1992;59-67.
37. Newton R., Broughton L.J., Lind M.J., Morrison P.J., Rogers H.J., Bradbrook I.D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol. 211:1981;45-52.
38. Tang-Liu D.D., Williams R.L., Riegelman S. Disposition of caffeine and its metabolites inman. J. Pharmacol. Exp. Ther. 224:1983;180-185.
39. Campbell M.E., Spielberg S.P., Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 42:1987;157-165.
40. Preifer R.W., Notari R.E. Predicting caffeine plasma concentrations resulting from consumption of food or beverages: A simple method and its origin. Drug Intell. Clin. Pharm. 22:1988;953-959.
41. Denaro C.P., Wilson M., Jacob III P., Benowitz N.L. The effect of liver disease on urine caffeine metabolite ratios. Clin. Pharmacol. Ther. 59:1996;624-635.
42. Adkin D.A., Davis S.S., Sparrow R.A., Wilding I.R. Colonic transit different sized tablets in healthy subjects. J. Control. Rel. 23:1933;147-156.
43. Kennedy M., Chinwah P., Wade D.N. A pharmacological method of measuring mouth caecal transit time in man. Br. J. Clin. Pharmacol. 8:1979;372-373.
44. Davis S.S., Washington N., Parc G.D. Relationship between the rate of appearance of oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. Br. J. Clin. Pharmacol. 26:1988;435-443.